INVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023

Apr 11, 2023 | Press Releases

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., April 11, 2023 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced infertility...

INVO Congratulates Wisconsin Fertility Institute on Being Named One of America’s Best Fertility Clinics by Newsweek

Apr 5, 2023 | Press Releases

INVO recently announced the signing of binding agreements to acquire this top-rated clinic SARASOTA, Fla. and MADISON, Wis., April 5, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility...

INVO Provides Preliminary Update on FY2022 Financial Results

Mar 30, 2023 | Press Releases

SARASOTA, Fla., March 30, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and...

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering

Mar 27, 2023 | Press Releases

SARASOTA, Fla., March 27, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and...

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market

Mar 24, 2023 | Press Releases

SARASOTA, Fla., March 24, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and...